Pluri (PLUR) Marketable Securities: $5.90 Mil (As of Mar. 2026)


PLUR Pluri Inc PLUR
29 GF Score
Price $1.72
GF Value $6.52
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Pluri Marketable Securities?

Pluri PLUR -3.65% 29 Marketable Securities is $5.90 Mil as of Mar. 2026. GuruFocus rates PLUR with a GF Score™ of 29/100 and a GF Value™ of $6.52 (Possible Value Trap). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Pluri's Marketable Securities for the quarter that ended in Mar. 2026 was $5.90 Mil.

Pluri's annual Marketable Securities declined from Jun. 2023 ($34.81 Mil) to Jun. 2024 ($23.20 Mil) and declined from Jun. 2024 ($23.20 Mil) to Jun. 2025 ($14.72 Mil).

Pluri  (NAS:PLUR) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Pluri Marketable Securities Related Terms

Pluri Marketable Securities Historical Data

* Premium members only.

The historical data trend for Pluri's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pluri Marketable Securities Chart

Pluri Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.71 45.24 34.81 23.20 14.72

Pluri Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.77 14.72 10.80 7.79 5.90
PLUR
29GF Score
Pluri Inc PLUR
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pluri Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $5.90 Mil mean?
Pluri (PLUR) has a Marketable Securities of $5.90 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pluri and its competitors.
Is Pluri's Marketable Securities too high?
Pluri's current Marketable Securities is $5.90 Mil. Overall, Pluri has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pluri's Marketable Securities compare to MRKR and VYNE?
Pluri's Marketable Securities of $5.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pluri and its competitors. Pluri's current Marketable Securities is $5.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Based on GuruFocus' analysis, Pluri (PLUR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.52, compared to a current price of $1.72 — trading 73.7% below its estimated fair value. The current Marketable Securities is $5.90 Mil. Pluri's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Pluri (PLUR), the current Marketable Securities is $5.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pluri (PLUR) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of $1.72 is trading 73.7% below its estimated GF Value™ of $6.52. GuruFocus considers Pluri to be Possible Value Trap.

Key valuation signals for PLUR:

  • Marketable Securities: $5.90 Mil
  • GF Value™: $6.52 vs. price of $1.72 (73.7% below fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pluri Business Description

Other Exchanges PLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
29GF Score

Get the complete analysis for PLUR

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price
$6.52
GF Value